There is a long-standing polemic concerning the usefulness of antidepressants in the treatment of major depressive disorder. In this paper we propose to highlight some aspects of this controversy by exploring the mutual influence of psychopharmacology and trial methodologies. Indeed, antidepressant efficacy, if not proved, was accepted before antidepressant randomised controlled trials (RCTs) were run. While RCTs became a gold standard to meet the requirements of the regulatory bodies, methodological tools were required to measure outcomes and to test whether antidepressants provide statistically significant benefits as compared with a placebo. All these methodological options have nonetheless introduced fuzziness in our interpretation of study results, in terms of clinical meaningfulness and in terms of transposability to a real life settings. Additionally, selective publication raises concerns about the published literature, and results in many paradoxes. Instead of providing easy answers, the application of the RCT paradigm in MDD raises numerous questions. This is probably in the nature of all scientific studies, but it can be in contradiction with clinicians' expectations, who want to be sure that the treatment will (or will not) work for their individual patients.
The idea of an antidepressant, and the discoveries about their 48 putative biological properties, reshaped the concept of depres-49 sion. A debate emerged concerning whether there was any value 50 in distinguishing "endogenous depression" and milder conditions 51 in relation with stressful events known as neurotic depression 52 (the Khun perspective) and treating them differently, or whether 53 there was no basis for separate categories of depression since they 54 all lie on a continuum of severity, as proposed by Akiskal and 55 Mc Kinney. [14] In 1980, the Diagnostic and Statistical Manual of 56 Mental Disorders (DSM) III [15] retained the latter view by com-57 bining the two entities under the label of major depressive disor-58 der (MDD).
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Non-scientific reasons have probably also contributed to the 60 wide acceptation of the concepts of antidepressant and MDD. [4] 61 Concerning the ideological conflict of interest, these concepts 62 were not in favour of the psychiatric profession's desire to inte-63 grate with general medicine and to counter attacks from the an-64 tipsychiatry movement. Concerning the financial conflict of inter-65 est, the pharmaceutical industry also had an interest in promoting 66 these concepts. [4] 67 3. RCTs became inescapable in the evaluation 68 of antidepressants 69 Alongside these conceptual changes randomized controlled 70 trials (RCTs) developed in the evaluation of medication. The Med-71 ical Research Council (MRC) ran the first RCT versus placebo in 72 1948 to explore the efficacy of streptomycin in tuberculosis. [16] 73 Previous non-randomized studies had established that strepto-74 mycin worked in the short term treatment of tuberculosis, but an a 75 posteriori interpretation of this trial is that it probably proved the 76 "efficacy of RCTs" rather than the efficacy of streptomycin. [17] In 77 the years following this trial, many RCTs were funded by national 78 public bodies, for example the MRC evaluation of imipramine 79 versus phenelzine, electroconvulsive therapy and placebo in the 80 relief of depressive illness. [18] These trials were often concerned 81 with broad questions regarding classes of treatments, rather than 82 specific compounds. [19] 83 After the thalidomide crisis in 1962, the Kefauver-Harris drug 84 amendments were passed to ensure drug efficacy and greater drug 85 safety. It was because medications entailed a risk that evidence 86 of efficacy was sought and, for the first time, drug manufactur-87 ers were required to prove to the Food and Drug Administra-88 tion (FDA) the efficacy of their products before marketing them. 89 Gradually, the situation changed, public funding declined and the 90 vast majority of clinical trials on drug treatments in psychiatry 91 were sponsored and conducted by the pharmaceutical industry, 1 the number of trials increased dramatically, trials concerned single 2 patented compounds and were designed to meet the requirements 3 of the regulatory bodies. [19] While for a large proportion of med-4 ical interventions, few or no clinical trials are ever conducted, for 5 antidepressants there are probably now well over a thousand. [20] Nonetheless, it should be noted that antidepressant efficacy, 10 if not proved, was accepted before antidepressant RCTs were run, 11 and that no antidepressant in the RCT era was proved to be supe-12 rior to imipramine in terms of efficacy. [21] Thus, being thought-13 provocative, one can say that antidepressants have made advances 14 in methodology possible, rather than stating that methodology has 15 enabled major advances in psychopharmacology for MDD. In- (MADRS), [22] a scale developed to be particularly sensitive to 29 treatment effects. It is nonetheless interesting that a scale that is to 30 be used to assess the difference between a treatment and a placebo 31 was developed to be particularly sensitive to specific changes oc-32 curring under treatment. The Clinical Global Impression [24] (CGI) 33 which rates severity on a scale of 1 to 7, was retained as a refer-34 ence for global assessment and some self-administered question-35 naires like the Beck Depression Inventory (BDI) among others 36 were popularised by the wide development of RCTs in MDD. [25] 37 Binary outcomes also had to be adopted, such as response and re-38 mission, which have meaning for clinicians. Despite the fact that 39 they are intuitive, their definition is not straightforward and a con-40 sensus emerged to derive these outcomes from continuous rating 41 scales by calculating the proportion of people who fall below pre-42 defined threshold scores, which tend to be validated merely by 43 convention and tradition. [26] Since 1991 [27] remission is defined 44 as a score 7 on the 17 items of the Hamilton Depression Rating 45 Scale (HDRS-17) and response is usually defined as a reduction 46 of 50% on the HDRS-17. While these methodological tools enable the measurement 50 of outcomes and test whether antidepressants provide statistically 51 significant benefits as compared with a placebo, there is a con-52 siderable debate concerning the real meaning of the difference in 53 term of its clinical significance. Indeed, the identification of a min-54 imal clinically relevant difference on a scale is not straightforward. 55 In 2004, the National Institute of Clinical Excellence [28] stated 56 that a Hamilton score difference of three points across groups 57 could be considered as clinically significant. This threshold was 58 consistent with previous research [29] but a recent linking anal-59 ysis provided new insight by suggesting that a slight reduction 60 on the HAMD-17 of up to 3 points corresponds to a rating of 61 "no change" as measured with the CGI. A change close to 10 62 points was linked to the "much improved" category defined by 63 the CGI. [30] But these considerations on an individual level are not 64 totally transposable to group level. On the other hand, this study 65 also suggested that the commonly used measures for response (1) 66 and remission (2) in MDD trials could reasonably be considered 67 valid because they were coherent with the CGI definitions "much 68 improved" (1) and "not at all" or "borderline mentally ill" (2), 69 respectively. Bearing in mind that the CGI is not a perfect gold 70 standard, these results are very interesting. 71 6. RCTs and the dilution of efficacy 72 To cope with the questions of variability and randomness, 73 randomised controlled trials (RCT) "tell stories" about average 74 patients, and the statistical inferences underpinning RCT conclu-75 sions concern expected values of random variables. [31] This type 76 of paradigm implies that sufficient efficacy in a subgroup of pa-77 tients can induce an impression of efficacy for the whole group, 78 providing the study is adequately powered. This "dilution" of 79 efficacy can occur especially in the case of heterogeneous cate-80 gories such as MDD. Recent meta-analyses have indeed shed new 81 light on this debate. Meta-analyses on aggregated data by Khan 82 et al. [32] and Kirsh et al. [33] suggested that the baseline severity of 83 depressive symptoms is related to clinical trial outcomes. These 84 two meta-analyses were based on FDA data (i.e. an exhaustive set 85 of studies) but were prone to an ecological fallacy [20] since they 86 were based on aggregated data. Nonetheless, their results were 87 reproduced by Fournier et al. within the framework of an indi-88 vidual data meta-analysis. [34] This study addressed the limitations 89 of aggregated data meta-analyses, but since personal data are dif-1 ficult to collect, it was prone to publication bias. Nevertheless, 2 these three meta-analyses concluded consistently that the distinc-3 tion between antidepressants and placebo is clinically meaningful 4 (using the National Institute for Clinical Excellence threshold for 5 clinical significance) only for severe and very severe patients.
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Interestingly, Gibbons et al. [35] addressed the limitations of 7 the preceding studies by reanalysing all intent-to-treat individual 8 longitudinal data during the first 6 weeks of treatment for major 9 depressive disorder from all sponsored randomized controlled tri-10 als on fluoxetine and venlafaxine. In this meta-analysis, average 11 differences at 6 weeks were small and not clinically meaningful
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(2.5 HAM-D units) and baseline severity was not shown to af- is common in clinical practice, [38, 39] and the number of follow-38 up assessments [40] is related to a significant therapeutic effect. [ But the RCTs included in Hrobjartsson's meta-analysis were not 49 designed (they were underpowered) to study the placebo effect 50 adequately. Similarly, in Kirsch's meta-analysis, which comprises 51 no "untreated group" or waiting list, we cannot determine the size 52 of the placebo effect. There is thus considerable debate about the 53 size, the nature and the mechanism of the placebo effect in de-54 pression. [42] For example, it has been proposed that the apparent 55 antidepressant effect could be in part an active placebo effect, or 56 result from bias, since side effects like sexual effects [45] of an-57 tidepressants could reveal the identity of the medication to partic-58 ipants or investigators. [46] 59 Nonetheless, while some general medical drugs have very 60 high effect sizes, the effect sizes obtained by psychiatric drugs are 61 in the same range as most general medical pharmaceuticals. [47] 62 Although it is difficult to compare effect sizes of drugs in different 63 conditions, indications and outcomes, this finding puts the small 64 effect sizes observed with antidepressants into perspective. 65 66 Antidepressants efficacy is nonetheless certainly overesti-67 mated in the published literature by selective publication and se-68 lective outcome reporting. To explore this phenomenon, Turner 69 et al. performed an analysis of 74 studies that were submitted 70 to FDA for the approval of 12 antidepressant drugs. Among these 71 studies, the FDA considered that 38 (51%) were "positive" (with a 72 statistically significant result on the principal outcome), 12 (16%) 73 "indeterminate" and 24 (33%) "negative" (with no statistically 74 significant result on the principal outcome). Among the "posi-75 tive" studies, 37 (97%) were published and only one (3%) was 76 not published. Among the "indeterminate" studies, 6 (50%) were 77 published as positive and 6 (50%) were unpublished. Finally, of 78 the "negative" studies, 3 (12%) were published as "negative", in 79 agreement with the opinion of the FDA, 5 (21%) were published 80 as "positive", in disagreement with the opinion of FDA and 16 81 (67%) were not published. The effect size measured by perform-82 ing a meta-analysis on the basis of published results is 0.41 with 83 a 95% confidence interval of [0.36-0.45], whereas it is estimated 84 to be 0.31 with a 95% confidence interval of [0.27-0.35] based on 85 all studies reported to FDA.
Overestimation and distortion of efficacy
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The best-documented case of selective outcome reporting 87 is probably study 329. [48] [49] [50] It was a large study of 275 de-88 pressed adolescents conducted by SmithKline Beecham in the US 89 from 1993-1996. Its results failed to show any statistically sig-90 nificant difference between paroxetine and placebo for the two 91 primary outcomes. A GSK internal document stated that the re-92 sults of study 329 indicated paroxetine was no more effective than 93 criteria (for example suicidal ideations) [65] [66] [67] and excluded pa-45 tients are a more chronically ill group with more numerous previ-46 ous episodes, greater psychosocial impairment, and more frequent 47 personality disorders. Finally, the vast majority of RCTs last no 48 more than 8 weeks, whereas it is recommended that an antidepres-49 sant treatment be continued for at least 6 months after remission 50 of the episode. [68] 51 There is debate as to whether these issues can be trans-52 lated into different outcomes between RCTs and a "real life" 53 setting. [69-72] 54 
Conclusion
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While meta-analyses should be reproducible, in 2013, a meta-56 analysis of published and unpublished studies on agomelatine 57 found "evidence suggesting that a clinically important difference 58 between agomelatine and placebo in patients with unipolar ma-59 jor depression was unlikely"; [73] in 2014 a meta-analysis of pub-60 lished and unpublished studies on agomelatine found that it "was 61 an effective antidepressant with similar efficacy to standard an-62 tidepressants". [74] This particular paradox sums up the fuzziness 63 of antidepressant literature. We suggest that, instead of providing 64 easy answers, the application of the RCT paradigm to MDD raises 65 many questions. This is probably in the nature of all scientific 66 studies, but it can be in contradiction with clinicians' expectations: 67 what they want is to be sure that the treatment will work for indi-68 vidual patients (or to know if it will not). At the same time, their 69 clinicial experience is biased by many other parameters, including 70 placebo response. This is precisely where the debate arises.
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